Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

doi:10.3390/ijms24119507

Review

. 2023 May 30;24(11):9507.

doi: 10.3390/ijms24119507.

Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Adrianna Radulska¹, Iwona Pelikant-Małecka¹, Kamila Jendernalik¹, Iwona T Dobrucki^{2

3

4}, Leszek Kalinowski^{1

5}

Affiliations

¹ Department of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211 Gdansk, Poland.
² Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, 405N Mathews Ave., MC-251, Urbana, IL 61801, USA.
³ Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
⁴ Carle-Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
⁵ BioTechMed Centre/Department of Mechanics of Materials and Structures, Gdansk University of Technology, 11/12 Narutowicza Street, 80-233 Gdansk, Poland.

PMID: 37298466
PMCID: PMC10253645
DOI: 10.3390/ijms24119507

Review

Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Adrianna Radulska et al. Int J Mol Sci. 2023.

. 2023 May 30;24(11):9507.

doi: 10.3390/ijms24119507.

Authors

Adrianna Radulska¹, Iwona Pelikant-Małecka¹, Kamila Jendernalik¹, Iwona T Dobrucki^{2

3

4}, Leszek Kalinowski^{1

5}

Affiliations

¹ Department of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211 Gdansk, Poland.
² Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, 405N Mathews Ave., MC-251, Urbana, IL 61801, USA.
³ Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
⁴ Carle-Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
⁵ BioTechMed Centre/Department of Mechanics of Materials and Structures, Gdansk University of Technology, 11/12 Narutowicza Street, 80-233 Gdansk, Poland.

PMID: 37298466
PMCID: PMC10253645
DOI: 10.3390/ijms24119507

Abstract

Skin diseases such as psoriasis (Ps) and psoriatic arthritis (PsA) are immune-mediated inflammatory diseases. Overlap of autoinflammatory and autoimmune conditions hinders diagnoses and identifying personalized patient treatments due to different psoriasis subtypes and the lack of verified biomarkers. Recently, proteomics and metabolomics have been intensively investigated in a broad range of skin diseases with the main purpose of identifying proteins and small molecules involved in the pathogenesis and development of the disease. This review discusses proteomics and metabolomics strategies and their utility in research and clinical practice in psoriasis and psoriasis arthritis. We summarize the studies, from in vivo models conducted on animals through academic research to clinical trials, and highlight their contribution to the discovery of biomarkers and targets for biological drugs.

Keywords: in vivo mouse models; metabolomics; proteomics; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
(A) Basic techniques used in proteomic/metabolomic analysis and their utility in psoriasis. (B) Catalogue of future candidate proteomic and metabolomic biomarkers differentiating psoriasis and psoriatic arthritis [100]. Black font represents biomarkers identified in both diseases and green/yellow fonts correspond, respectively, to Ps and PsA.

See this image and copyright information in PMC

Cited by

Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study.
Xu X, Wu LY, Wang SY, Yan M, Wang YH, Li L, Sun ZL, Zhao JX. Xu X, et al. Front Microbiol. 2024 Feb 15;15:1287637. doi: 10.3389/fmicb.2024.1287637. eCollection 2024. Front Microbiol. 2024. PMID: 38426052 Free PMC article.
The Relationship Between Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index Markers and Response to Biological Therapy in Patients with Psoriasis.
Kimak-Pielas A, Robak E, Zajdel R, Żebrowska A. Kimak-Pielas A, et al. Int J Mol Sci. 2025 Apr 19;26(8):3868. doi: 10.3390/ijms26083868. Int J Mol Sci. 2025. PMID: 40332589 Free PMC article.
Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis.
Rusiñol L, Puig L. Rusiñol L, et al. Int J Mol Sci. 2024 Jan 15;25(2):1042. doi: 10.3390/ijms25021042. Int J Mol Sci. 2024. PMID: 38256115 Free PMC article. Review.

References

1. Yan D., Gudjonsson J.E., Le S., Maverakis E., Plazyo O., Ritchlin C., Scher J.U., Singh R., Ward N.L., Bell S., et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J. Investig. Dermatol. 2021;141:2112–2122.e3. doi: 10.1016/j.jid.2021.02.764. - DOI - PMC - PubMed
1. Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed
1. Borzęcki A., Koncewicz A., Raszewska-Famielec M., Dudra-Jastrzębska M. Epidemiology of Psoriasis in the Years 2008–2015 in Poland. Przegl. Dermatol. 2018;105:693–700. doi: 10.5114/dr.2018.80837. - DOI
1. Purzycka-Bohdan D., Kisielnicka A., Zabłotna M., Nedoszytko B., Nowicki R.J., Reich A., Samotij D., Szczęch J., Krasowska D., Bartosińska J., et al. Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life. J. Clin. Med. 2022;11:1254. doi: 10.3390/jcm11051254. - DOI - PMC - PubMed
1. Michalek I.M., Loring B., John S.M. A Systematic Review of Worldwide Epidemiology of Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:205–212. doi: 10.1111/jdv.13854. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Yan D., Gudjonsson J.E., Le S., Maverakis E., Plazyo O., Ritchlin C., Scher J.U., Singh R., Ward N.L., Bell S., et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J. Investig. Dermatol. 2021;141:2112–2122.e3. doi: 10.1016/j.jid.2021.02.764. - DOI - PMC - PubMed

[2] Yan D., Gudjonsson J.E., Le S., Maverakis E., Plazyo O., Ritchlin C., Scher J.U., Singh R., Ward N.L., Bell S., et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J. Investig. Dermatol. 2021;141:2112–2122.e3. doi: 10.1016/j.jid.2021.02.764. - DOI - PMC - PubMed

[3] Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed

[4] Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed

[5] Borzęcki A., Koncewicz A., Raszewska-Famielec M., Dudra-Jastrzębska M. Epidemiology of Psoriasis in the Years 2008–2015 in Poland. Przegl. Dermatol. 2018;105:693–700. doi: 10.5114/dr.2018.80837. - DOI

[6] Borzęcki A., Koncewicz A., Raszewska-Famielec M., Dudra-Jastrzębska M. Epidemiology of Psoriasis in the Years 2008–2015 in Poland. Przegl. Dermatol. 2018;105:693–700. doi: 10.5114/dr.2018.80837. - DOI

[7] Purzycka-Bohdan D., Kisielnicka A., Zabłotna M., Nedoszytko B., Nowicki R.J., Reich A., Samotij D., Szczęch J., Krasowska D., Bartosińska J., et al. Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life. J. Clin. Med. 2022;11:1254. doi: 10.3390/jcm11051254. - DOI - PMC - PubMed

[8] Purzycka-Bohdan D., Kisielnicka A., Zabłotna M., Nedoszytko B., Nowicki R.J., Reich A., Samotij D., Szczęch J., Krasowska D., Bartosińska J., et al. Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life. J. Clin. Med. 2022;11:1254. doi: 10.3390/jcm11051254. - DOI - PMC - PubMed

[9] Michalek I.M., Loring B., John S.M. A Systematic Review of Worldwide Epidemiology of Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:205–212. doi: 10.1111/jdv.13854. - DOI - PubMed

[10] Michalek I.M., Loring B., John S.M. A Systematic Review of Worldwide Epidemiology of Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:205–212. doi: 10.1111/jdv.13854. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Affiliations

Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous